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Background: Exacerbations are a defining outcome of chronic obstructive pulmonary disease
(COPD). We evaluated the effect of tiotropium on COPD exacerbations and related hospitali-
zations among patients from the USA enrolled in clinical trials.
Methods: Data were pooled from six randomized, double-blind, placebo-controlled trials (6 to
12 months’ duration) of tiotropium in patients with COPD. Exacerbations were defined retro-
spectively as an increase in or new onset of >1 respiratory symptom lasting for 3 days and0 617 5256; fax: þ1 210 949 3006.
edu (A. Anzueto).
hed by Elsevier Ltd.
13.07.020
Open access under CC BY-NC-ND license.
Impact of tiotropium on COPD exacerbations 1913requiring treatment with systemic corticosteroids and/or antibiotics. Time to first exacerba-
tion or hospitalization and exacerbation rates were analyzed at 6 months, and at 1 year for
studies 1 year.
Results: In total, 4355 patients (tiotropium, 2268, placebo, 2087; mean age 66.5 years; forced
expiratory volume in 1 s [FEV1] 1.03 L [35.5% predicted]) were analyzed at 6 months and 2455
at 1 year (tiotropium 1317, placebo 1138; mean age 65.5 years; FEV1 1.03 L [37.0% predicted]).
Tiotropium delayed time to first exacerbation or first hospitalized exacerbation at 6 months
(hazard ratios [HRs], 0.80, 0.65, respectively; p < 0.001 vs placebo) and 1 year (HRs, 0.73
and 0.55; p < 0.001 vs placebo) and reduced exacerbation rates and hospitalization rates (6
months: HRs, 0.79, 0.64; 1 year: HRs, 0.78, 0.56, respectively; all p < 0.01 vs placebo). Tiotro-
pium significantly reduced exacerbations, irrespective of inhaled corticosteroid use at base-
line. Tiotropium was not associated with an increased risk of cardiac-related events.
Conclusions: Tiotropium significantly reduced the risk and rates of exacerbations and hospital-
izations among US patients with COPD.
ª 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of disability and death worldwide [1e3] and is char-
acterized by a progressive decline in lung function and
periodic exacerbations of respiratory symptoms [4]. As
COPD progresses, the exacerbation incidence increases
[5,6]; however, patients with any Global Initiative for
Chronic Obstructive Lung Disease stage may experience
exacerbations that impact on their life, health status, and
prognosis [7]. Frequent exacerbations are associated with a
more rapid decline in lung function (forced expiratory
volume in 1 s [FEV1]) [5,8], diminished patient quality of
life [9], and increased mortality [10]. Death rates for pa-
tients hospitalized for a COPD exacerbation reportedly
range from 4 to 30% [11]. COPD exacerbations also incur a
substantial health economic burden [12e14]. Hospitaliza-
tion due to an exacerbation is particularly costly [15], and
has been estimated to consume 68% of medical expenses
for patients with COPD [16]. Consequently, preventing a
COPD exacerbation is an important management goal [17].
Tiotropium reduced COPD exacerbations in several
clinical trials when compared with placebo [18e20] and
salmeterol [21]. However, the actual treatment received by
patients with a COPD exacerbation (particularly in hospital
or emergency room [ER] settings) frequently deviates from
best practice recommendations, creating variation be-
tween countries and treatment centers [22e25]. The like-
lihood of hospitalization for a COPD exacerbation may also
show regional discrepancies [26e28].
Country-specific data on the risk and rates of exacerba-
tions in COPD patients receiving long-term maintenance
therapy will help to guide healthcare decisions relating to
additional COPD treatment and resource utilization. Exac-
erbation rates for patients receiving the same maintenance
treatment may vary between countries due to differences in
healthcare systems. By analyzing the data for one country
only, this helps to remove some of this potential bias.
We conducted a pooled analysis to evaluate the effect of
tiotropium on COPD exacerbations and hospitalizations in
patients resident in the United States based on collated
data from previously published trials.Methods
Study design
This retrospective, non-prespecified pooled analysis
included all Boehringer Ingelheim/Pfizer-sponsored pla-
cebo-controlled trials of 6 months’ duration that enrolled
patients from the United States, assessed tiotropium (SPI-
RIVA, Boehringer Ingelheim International GmbH, Ingel-
heim, Germany, and Pfizer Inc, New York, USA) in patients
with COPD, and included exacerbations as an outcome.
Completed trials with full reports available from December
31, 2010, were included. Six trials met these criteria (e-
Table 1) [18e20,29e31].
Concomitant medication was permitted in all studies (e-
Table 1), including all respiratory medications except other
inhaled anticholinergics in two studies [19,20]. In three
studies, other inhaled anticholinergics or long-acting b2-
agonist (LABA) medication use was not permitted
[18,29,31]. Patients could use a salbutamol metered-dose
inhaler as needed for symptom relief; theophylline,
inhaled corticosteroid (ICS) monotherapy, or oral steroids
(up to the equivalent of prednisolone, 10 mg/day).
For this pooled analysis, the following exacerbation
definition was applied: an increase in, or new onset of >1
respiratory symptom (cough, sputum, wheezing, dyspnea),
lasting for 3 days, and requiring treatment with systemic
corticosteroids and/or antibiotics. Exacerbations requiring
hospitalization were collated separately.
Analyses were performed at 6 months (all trials) and at 1
year for trials of 1-year duration.Patients
Inclusion criteria were a clinical diagnosis of COPD, age 40
years, smoking history of10 pack-years, postbronchodilator
FEV1 of 65e70% predicted, and FEV1/forced vital capacity
of 70%.
Key exclusion criteria are listed online in e-Table 2. All
studies excluded patients with a history/diagnosis of
asthma.
1914 A. Anzueto et al.Assessments
Patient baseline demographics, lung function, pulmonary
medication use, and concomitant disease prevalence were
recorded. COPD exacerbations and hospitalized exacerba-
tions were characterized by time to first event and number.
Safety evaluations included collating of adverse events
(AEs), serious AEs, and all-cause mortality.Statistical analyses
Exacerbations with onset during treatment (or until day of
last contact for the Veterans’ Affairs Medical Center study)
[19] and 6 months or 1 year since treatment start were
included in the pooled analysis. Follow-up of dropout
patients was only performed in study number 205.266.Table 1 Patient baseline characteristics.
Analysis Tiotropium
6 months 1 year
Patients, n 2268 1317
Age (SD), y 66.3 (8.5) 65.5 (8.2)
Male sex, % 78.7 65.3
Smoking status
Current smoker, % 31.0 32.1
Smoking history (SD), pack-years 63.9 (33.0) 61.6 (31.0
COPD duration (SD), y 10.4 (8.8) 9.2 (7.4)
BMI (kg/m2), %
<20 7.5 7.4
20e25 31.4 33.3
25e30 33.9 33.3
30 27.2 26.0
FEV1 (SD), L 1.04 (0.41) 1.04 (0.41
FEV1 (SD), % predicted 35.8 (12.6) 37.3 (13.0
FVC (SD), L 2.31 (0.77) 2.41 (0.82
FVC (SD), % predicted 62.7 (18.5) 68.4 (18.4
FEV1/FVC (SD) 0.45 (0.12) 0.44 (0.11
GOLD stage, %
I þ II 15.6 19.4
III 47.5 47.5
IV 36.2 32.0
Pulmonary medicine use, % 91.5 88.3
SAAC 64.2 53.3
SABA 82.1 76.7
LABA 35.6 34.2
ICS 54.6 49.4
LABA use alone 7.4 7.2
ICS use alone 26.4 22.4
LABA þ ICS use: free or fixed dose 28.2 27.0
LABA þ ICS use: fixed dose 9.7 15.4
Xanthines 15.3 15.3
No patients were using long-acting anticholinergics at baseline.
BMI: body mass index; COPD: chronic obstructive pulmonary disease;
GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICS: in
acting anticholinergic; SABA: short-acting b2-agonist; SD: standard deTime to first exacerbation/first hospitalized exacerba-
tion and associated hazard ratios (HRs) and 95% confidence
intervals (CIs) for tiotropium/placebo for the risk of an
event were calculated using Cox regression with trial as the
stratification variable. The analyses were rerun adding the
interaction term trial ) treatment.
Exacerbation rate ratios (RRs) were generated by
comparing the number of exacerbations between study
groups using Poisson regression analysis and correcting for
treatment exposure and overdispersion. Trial was included
as a stratification variable. The analyses were rerun adding
the interaction term trial ) treatment.
Subgroup analyses were performed for both time to event
and number of event, with use of “ICS either alone or with a
LABA” and “LABA either alone or with an ICS” at baseline as
subgroup variables. The analyses were rerun adding the
interaction term subgroup * treatment. The LABA subgroupPlacebo Total
6 months 1 year 6 months 1 year
2087 1138 4355 2455
66.7 (8.5) 65.6 (8.3) 66.5 (8.5) 65.5 (8.2)
78.9 63.4 78.8 64.4
30.5 30.5 30.7 31.4
) 64.2 (34.5) 60.3 (32.3) 64.1 (33.7) 61.0 (31.7)
10.4 (9.0) 9.2 (7.3) 10.4 (8.9) 9.2 (7.3)
9.3 9.7 8.4 8.4
29.7 31.6 30.6 32.5
34.6 34.6 34.2 33.9
26.4 24.0 26.8 25.1
) 1.02 (0.41) 1.02 (0.42) 1.03 (0.41) 1.03 (0.42)
) 35.2 (12.5) 36.6 (12.8) 35.5 (12.6) 37.0 (12.9)
) 2.30 (0.78) 2.41 (0.85) 2.31 (0.77) 2.41 (0.84)
) 62.1 (18.4) 68.7 (18.6) 62.4 (18.4) 68.6 (18.5)
) 0.45 (0.11) 0.43 (0.11) 0.45 (0.11) 0.43 (0.11)
14.5 17.6 15.1 18.5
46.6 46.6 47.0 47.1
37.9 33.9 37.0 32.9
92.4 89.6 91.9 88.9
65.9 55.3 65.0 54.2
84.4 78.9 83.2 77.7
38.1 38.7 36.8 36.3
53.9 50.4 54.2 49.9
9.2 7.9 8.3 8.0
25.0 20.6 25.7 21.5
28.8 29.8 28.5 28.3
10.1 17.3 9.9 16.3
13.2 13.7 14.3 14.6
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;
haled corticosteroid; LABA: long-acting b2-agonist; SAAC: short-
viation.
Impact of tiotropium on COPD exacerbations 1915analysis was restricted to trials allowing LABAs as concomi-
tant medication and included patients receiving combined
LABA/ICS.
Adverse event incidence rates were computed as the
number of patients experiencing an event (during
treatment þ 30 days, censored at day 182 [6 months] or 365
[1 year]), divided by the person-years at risk. Time at risk
was defined as minimum (182 or 365, time till death, time
of exposure þ 30 days) for subjects not experiencing an
event, and time from start of treatment to onset for sub-
jects who experienced an event at day 182/365, whichever
came earlier. To measure the effect strength, incidence
ratios for tiotropium vs placebo were calculated using the
CochraneManteleHaenszel test, stratified by study. Rate
ratios <1 indicated a decreased risk with tiotropium; an
RR > 1 indicates a decreased risk with placebo.Results
Baseline characteristics
A total of 4355 patients (tiotropium, 2268/placebo, 2087)
were included in the analysis of data from studies 6
months’ duration; 2455 patients (tiotropium, 1317/placebo
1138) were also included in analysis of data from studies
1-year duration. Baseline characteristics (Table 1) and
baseline comorbidities (e-Table 3) were balanced between
the tiotropium and placebo groups in both analyses.
e-Table 4 shows the number of patients in each study.Figure 1 Cumulative incidence for A) Time to first exacerbation
first hospitalized exacerbation until 6 months for studies of 6 m
studies of 1-year duration; D) Time to first hospitalized exacerbat
interval; COPD, chronic obstructive pulmonary disease.Time to first exacerbation and hospitalized
exacerbation
Tiotropium delayed the time to first exacerbation and time
to first hospitalized exacerbation, corresponding to
reduced risks of both events by 6 months (HR, 0.80; 95% CI,
0.71e0.89 and HR, 0.65; 95% CI, 0.51e0.83, respectively;
both p < 0.001) (Fig. 1A and B). There was no
trial ) treatment interaction (p > 0.58 and p > 0.86,
respectively).
A similar pattern was seen with events occurring by 1
year, with tiotropium delaying time to first exacerba-
tion (HR, 0.73; 95% CI, 0.65e0.83; p < 0.001) (Fig. 1C)
and hospitalized exacerbations (HR, 0.55; 95% CI,
0.42e0.73; p < 0.001) (Fig. 1D). There was no
trial ) treatment interaction (p > 0.62 and p > 0.83,
respectively).
Table 2 shows the analysis of time to first COPD exac-
erbation/exacerbation leading to hospitalization (events
occurring until 6 months and 1 year) according to treat-
ment group and LABA or ICS use at baseline. There were no
subgroup ) treatment interactions (p > 0.1). At both time
points, tiotropium significantly reduced the number of
exacerbations and hospitalized exacerbations vs placebo,
irrespective of whether patients were receiving ICS at
baseline. Tiotropium also reduced exacerbations and hos-
pitalized exacerbations vs placebo by 6 months and 1 year
in the LABA use or no LABA use subgroups, although some
subgroup comparisons did not reach statistical
significance.until 6 months for studies of 6 months’ duration; B) Time to
onths’ duration; C) Time to first exacerbation until 1 year for
ion until 1 year for studies of 1-year duration. CI: confidence
Table 2 Analysis of time to first exacerbation and first hospitalized exacerbation (Cox regression) for patients using ICS or
LABA at baseline.
Subgroup Tiotropium Placebo Subgroup by
treatment
interaction
p-value
Tiotropium/placebo
Number of
patients
treated
Number of
patients
with event
Number of
patients
treated
Number of
patients
with event
HR (95% CI) p-Value
By 6 months (cut-off day 182)a
Time to first
exacerbation
analysis
ICS use 1238 363 1124 398 0.6312 0.76 (0.66e0.88) 0.0002
No ICS use 1030 210 963 230 0.81 (0.67e0.98) 0.0268
LABA use 768 227 763 279 0.3451 0.74 (0.62e0.88) 0.0008
No LABA
use
913 214 919 247 0.84 (0.70e1.01) 0.0572
Time to first
hospitalized
exacerbation
analysis
ICS use 1238 71 1124 98 0.9992 0.62 (0.46e0.84) 0.0022
No ICS use 1030 36 963 52 0.62 (0.41e0.95) 0.0296
LABA use 768 50 763 66 0.8127 0.71 (0.49e1.03) 0.0694
No LABA
use
913 43 919 63 0.67 (0.45e0.98) 0.0409
By 1 year (cut-off day 365)
Time to first
exacerbation
analysis
ICS use 651 261 573 288 0.1214 0.67 (0.56e0.79) <0.0001
No ICS use 666 204 565 198 0.82 (0.67e0.99) 0.0409
LABA use 422 173 412 211 0.2898 0.67 (0.54e0.81) <0.0001
No LABA
use
345 110 355 131 0.79 (0.62e1.02) 0.0755
Time to first
hospitalized
exacerbation
analysis
ICS use 651 49 573 75 0.5593 0.51 (0.35e0.73) 0.0002
No ICS use 666 36 565 48 0.60 (0.39e0.93) 0.0211
LABA use 422 42 412 56 0.1314 0.66 (0.44e0.99) 0.0431
No LABA
use
345 13 355 33 0.37 (0.19e0.70) 0.0024
HR and p-value based on subgroup restricted Cox regression with treatment as covariate. Subgroup by treatment interaction p-value
based on Cox regression adjusted for treatment, subgroup and subgroup-by-treatment interaction.
CI: confidence interval; HR: hazard ratio; ICS: inhaled corticosteroid; LABA: long-acting b2-agonist.
a In trial 205.266, exacerbations until the date of last contact are also included. The LABA as well as the ICS subgroup also included
patients on LABA/ICS combination.
1916 A. Anzueto et al.Rates of exacerbations and hospitalized
exacerbations
Tiotropium significantly reduced the rate of exacerbations
and hospitalized exacerbations by the 6-month and 1-year
time points (Tables 3 and 4).
Table 5 shows the rates of exacerbations and hospital-
ized exacerbations (events occurring until 6 months and 1Table 3 Annual exacerbation rates and RRs at 6 months in stud
Tiotropium (n Z 2268) Placebo (n
Number
of events
Rate per
patient-year
(95% CI)
Number of
Exacerbations 786 0.73 (0.60e0.90) 890
Hospitalized
exacerbations
124 0.10 (0.05e0.17) 178
RRs were calculated with the use of Poisson regression corrected for t
variable. p-Value for trial ) treatment interaction: 0.3467/0.5782.
CI: confidence interval; RR: rate ratio.
a In trial 205.266, exacerbations until the date of last contact are ayear) according to treatment group and LABA or ICS use at
baseline. There were no subgroup ) treatment interactions
(p > 0.05). At both time points, tiotropium reduced exac-
erbations and exacerbations requiring hospitalization
compared with placebo, irrespective of whether patients
were receiving LABA or ICS at baseline (although
some subgroup comparisons did not reach statistical
significance).ies 6 months’ duration.a
Z 2087) Tiotropium/placebo
events Rate per
patient-year
(95% CI)
RR (95% CI) p-Value
0.93 (0.76e1.13) 0.79 (0.70e0.89) 0.0001
0.15 (0.08e0.27) 0.64 (0.46e0.89) 0.0079
reatment exposure and overdispersion with trial as a stratification
lso included.
Table 4 Annual exacerbation rates and RRs at 1 year in studies of 1-year duration.
Tiotropium (n Z 1317) Placebo (n Z 1138) Tiotropium/placebo
Number of
events
Rate per patient-year
(95% CI)
Number of
events
Rate per patient-year
(95% CI)
RR (95% CI) p-Value
Exacerbations 750 0.67 (0.60e0.75) 775 0.86 (0.77e0.96) 0.78 (0.68e0.90) <0.001
Hospitalized
exacerbations
98 0.09 (0.06e0.12) 141 0.15 (0.11e0.21) 0.56 (0.38e0.84) 0.005
RRs were calculated with the use of Poisson regression corrected for treatment exposure and overdispersion with trial as a stratification
variable. p Value for trial ) treatment interaction: 0.5619/0.9642.
CI: confidence interval; RR: rate ratio.
Impact of tiotropium on COPD exacerbations 1917Adverse events
Table 6 shows the most common AEs reported in this pooled
analysis. The total incidence of AEs was 58.7% in the tio-
tropium group compared with 56.3% in the placebo group
(RR, 0.88; 95% CI, 0.81e0.95). The most frequently speci-
fied AEs were “COPD” (21.6% vs 25.3%; RR, 0.72; 95% CI,Table 5 Exacerbation rates and RRs for patients using ICS or LA
Tiotropium Placebo
Number
of
events
Adjusted rate
of events per
patient-year
Numbe
of
events
By 6 months (cut-off day 182)a
Exacerbations ICS use 1238 0.86 (0.77e0.96) 1124
No ICS use 1030 0.58 (0.50e0.67) 963
LABA use 768 0.88 (0.77e1.00) 763
No LABA
use
913 0.66 (0.58e0.77) 919
Exacerbations
leading to
hospitalization
ICS use 1238 0.14 (0.10e0.19) 1124
No ICS use 1030 0.09 (0.06e0.13) 963
LABA use 768 0.15 (0.11e0.21) 763
No LABA
use
913 0.12 (0.09e0.17) 919
By 1 year (cut-off day 365)
Exacerbations ICS use 651 0.77 (0.68e0.88) 573
No ICS use 666 0.57 (0.49e0.66) 565
LABA use 422 0.76 (0.65e0.89) 412
No LABA
use
345 0.54 (0.44e0.67) 355
Exacerbations
leading to
hospitalization
ICS use 651 0.10 (0.07e0.15) 573
No ICS use 666 0.07 (0.05e0.12) 565
LABA use 422 0.12 (0.08e0.19) 412
No LABA
use
345 0.05 (0.02e0.10) 355
RRs were calculated with the use of Poisson regression corrected
stratification variable. Subgroup by treatment interaction p-value i
treatment interaction in addition.
CI: confidence interval; ICS: inhaled corticosteroid; LABA: long-acting
a In trial 205.266, exacerbations until the date of last contact are als
combination.0.63e0.81) and “upper respiratory tract infection” (12.7%
vs 10.1%; RR, 0.98; 95% CI, 0.82e1.17).
The incidence of serious AEs was 19.1% with tiotropium
group and 20.6% with placebo (RR, 0.86; 95% CI, 0.75e0.98)
(Table 7). The most frequent serious AE was COPD (114
[5.0%] for tiotropium and 173 [8.3%] for placebo; RR, 0.55;
95% CI, 0.44e0.70). The risk of serious cardiac events wasBA at baseline.
Subgroup by
treatment
interaction
p-value
Tiotropium/placebo
r Adjusted rate
of events per
patient-year
RR (95% CI) p-Value
1.14 (1.03e1.27) 0.4967 0.75 (0.65e0.88) 0.0002
0.70 (0.61e0.81) 0.82 (0.67e1.01) 0.0602
1.15 (1.02e1.30) 0.5285 0.76 (0.64e0.91) 0.0034
0.80 (0.70e0.91) 0.83 (0.68e1.01) 0.0606
0.23 (0.18e0.30) 0.9278 0.61 (0.41e0.89) 0.0109
0.14 (0.10e0.20) 0.62 (0.37e1.07) 0.0861
0.23 (0.17e0.30) 0.8358 0.65 (0.42e1.00) 0.0519
0.18 (0.13e0.23) 0.69 (0.45e1.08) 0.1079
1.10 (0.98e1.25) 0.0586 0.70 (0.59e0.84) <0.0001
0.62 (0.53e0.72) 0.92 (0.74e1.15) 0.4609
1.04 (0.90e1.20) 0.3581 0.74 (0.60e0.91) 0.0043
0.63 (0.52e0.76) 0.87 (0.65e1.15) 0.3248
0.20 (0.14e0.27) 0.6453 0.52 (0.31e0.87) 0.0131
0.12 (0.08e0.18) 0.63 (0.33e1.19) 0.1518
0.19 (0.13e0.26) 0.2194 0.67 (0.39e1.14) 0.1380
0.13 (0.08e0.20) 0.36 (0.15e0.85) 0.0200
for treatment exposure and overdispersion with subgroup as a
s based on the same Poisson regression including subgroup-by-
b2-agonist; RR: rate ratio.
o included. The LABA subgroup also included patients on LABA/ICS
Table 6 AEs: incidence and rate (5% in any group) by MedDRA SOC and PT.
SOC/PT Tiotropium (n Z 2268) Placebo (n Z 2087) RR (95% CI)
Incidence
(%)
Rate per 100
patient-years
Incidence
(%)
Rate per 100
patient-years
Total AEs 58.7 152.60 56.3 156.75 0.88 (0.81e0.95)a
Cardiac 6.0 8.31 7.0 10.76 0.78 (0.61e0.98)a
Gastrointestinal disorders 16.5 25.72 11.7 19.02 1.25 (1.06e1.47)a
General disorders and
administration-site
conditions
10.1 14.56 8.1 12.63 1.00 (0.82e1.22)
Infections and infestations 31.3 54.67 29.5 55.43 0.91 (0.81e1.01)
Sinusitis 5.1 7.13 4.1 6.27 1.04 (0.78e1.37)
Upper respiratory
tract infection
12.7 18.88 10.1 16.07 0.98 (0.82e1.17)
Injury, poisoning, and
procedural complications
6.9 9.75 5.4 8.29 1.09 (0.85e1.39)
Musculoskeletal and
connective tissue disorders
10.5 15.47 7.8 12.25 1.17 (0.96e1.43)
Nervous system disorders 8.6 12.38 8.4 13.31 0.82 (0.67e1.00)a
Respiratory, thoracic, and
mediastinal disorders
30.5 52.42 33.8 65.20 0.76 (0.69e0.85)a
COPD 21.6 34.20 25.3 45.03 0.72 (0.63e0.81)a
Rate per 100 patient-years is derived as 100 * (number of patients with event)/sum of time at risk. For each type of AE, time at risk is
time till onset of AE for patients with AE or time on treatment þ 30 days for patients without AE. RRs were calculated based on a
CochraneManteleHaenszel test stratified by trial.
AE: adverse event; CI: confidence interval; COPD: chronic obstructive pulmonary disease; MedDRA: Medical Dictionary for Regulatory
Activities; PT: preferred term; RR: rate ratio; SOC: system organ class.
a Ratio significantly different from 1.
1918 A. Anzueto et al.lower with tiotropium than with placebo (3.5% vs 4.9%; RR,
0.67; 95% CI, 0.50e0.90). The fatality incidence was the
same (73 [3.2%] for tiotropium and 67 [3.2%] for placebo,
RR, 0.98; 95% CI, 0.70e1.36). The most frequent cause of
deaths was COPD (8 [0.4%] for tiotropium and 14 [0.7%] for
placebo; RR, 0.53; 95% CI, 0.22e1.24).Discussion
We conducted a pooled analysis of exacerbations from
randomized, double-blind, placebo-controlled trials at both
6 months and 1 year, in the United States. Tiotropium
significantly delayed the time to an exacerbation and time
to a hospitalized exacerbation at both time points, indi-
cating a reduced risk of both events (p < 0.001). Tiotropium
also significantly reduced the rate of exacerbations and
hospitalized exacerbations at both 6 months (p Z 0.0001
and p Z 0.0079, respectively) and 1 year (p < 0.001 and
p Z 0.005, respectively). Supporting these data, a meta-
analysis of several trials previously showed that tio-
tropium reduces the risk of COPD exacerbations, including
those leading to hospital admission [32].
For patients with moderate to very severe COPD, current
guidelines recommend regular maintenance treatment with
a long-acting bronchodilator [33]. Aside from the reported
benefits of tiotropium (for up to 4 years of treatment) [20],
a reduction in COPD exacerbations vs placebo has also been
shown with salmeterol over 3 years (alone or combined withfluticasone propionate) [34] and indacaterol over 12e52
weeks of treatment [35e39]. No significant benefit on
moderate to severe exacerbations has been demonstrated
for formoterol, although a trial has yet to be designed to
examine this outcome specifically [40,41]. While no single
long-acting bronchodilator is recommended over another in
current guidelines [33,42,43], the Prevention Of Exacerba-
tions with Tiotropium in COPD (POET-COPD) trial
(N Z 7376) demonstrated that tiotropium is significantly
more effective than salmeterol in reducing risk and annual
exacerbation rates in moderate to very severe disease,
irrespective of concomitant ICS use [21]. Current guidelines
support adding ICS to bronchodilator treatment in patients
with severe COPD and a history of repeated exacerbations
[33,42], although when to select combination therapy over
monotherapy is not clearly established [43]. The long-
acting phosphodiesterase type 4 inhibitor, roflumilast, has
been shown to reduce exacerbations significantly in pa-
tients with severe COPD and a history of chronic bronchitis
and at least one exacerbation in the previous year,
regardless of whether they were receiving a LABA or a
short-acting anticholinergic [44].
Our analysis of time to first event by treatment group
showed that tiotropium reduced COPD exacerbations and
hospitalized exacerbations at 6 months and 1 year in both
the ICS use and no ICS use subgroups. However, the rates of
exacerbations and hospitalized exacerbations were not
significantly different to placebo in the no ICS subgroup. In
patients receiving long-acting bronchodilators at baseline,
Table 7 Serious and fatal AEs incidence and rate (1% in any group) by MedDRA SOC and PT.
SOC/PT Tiotropium (n Z 2268) Placebo (n Z 2087) RR (95% CI)
Incidence
(%)
Incidence per
100 patient-years
Incidence
(%)
Incidence per
100 patient-years
Total serious AEs 19.1 28.63 20.6 34.05 0.86 (0.75e0.98)a
Cardiac disorders 3.5 4.86 4.9 7.44 0.67 (0.50e0.90)a
Cardiac failure congestive 0.7 0.90 1.3 1.99 0.50 (0.27e0.93)a
Gastrointestinal disorders 1.8 2.41 1.7 2.57 0.95 (0.60e1.48)
General disorders and
administration site conditions
1.6 2.16 1.1 1.71 1.26 (0.76e2.11)
Infections and infestations 4.5 6.21 5.9 9.01 0.72 (0.55e0.93)a
Pneumonia 2.4 3.26 3.4 5.17 0.64 (0.45e0.91)a
Metabolism and nutrition disorders 1.0 1.32 0.9 1.35 1.00 (0.53e1.88)
Neoplasms benign, malignant,
and unspecified
3.0 4.12 2.6 3.94 1.06 (0.74e1.51)
Nervous system disorders 1.5 2.11 1.5 2.21 0.97 (0.60e1.59)
Respiratory, thoracic, and
mediastinal disorders
6.9 9.63 9.2 14.20 0.69 (0.56e0.86)a
COPD 5.0 6.97 8.3 12.71 0.55 (0.44e0.70)a
Vascular disorders 1.1 1.56 0.9 1.35 1.18 (0.66e2.11)
Total with fatal AEsb 3.2 4.42 3.2 4.80 0.98 (0.70e1.36)
Respiratory, thoracic, and
mediastinal disordersb
0.8 1.14 1.1 1.71 0.73 (0.40e1.33)
Rate per 100 patient-years is derived as 100 * (number of patients with event)/sum of time at risk. For each type of AE, time at risk is
time till onset of AE for patients with AE or time on treatment þ 30 days for patients without AE. RRs were calculated based on a
CochraneManteleHaenszel test stratified by trial.
AE: adverse event; CI: confidence interval; COPD: chronic obstructive pulmonary disease; MedDRA: Medical Dictionary for Regulatory
Activities; PT: preferred term; RR: rate ratio; SOC: system organ class.
a Ratio significantly different from 1.
b Incidence of fatal AEs.
Impact of tiotropium on COPD exacerbations 1919tiotropium reduced time to first exacerbation and hospi-
talized exacerbations at 6 months and 1 year (with p-
values < 0.05, except for hospitalized exacerbations,
p Z 0.0694); this subgroup had a relatively small sample
size (patients from the Understanding Potential Long-term
Impacts on Function with Tiotropium [UPLIFT] and
205.266 studies only). Our results suggest that the reduc-
tion in exacerbations with tiotropium vs placebo was not
consistently related to the use of LABA and/or ICS therapy
at baseline.
The data reported here are specific to patients in the
United States and are important for health professionals
and insurers based in this country. This is because they
provide an insight into the proportion of patients likely to
experience exacerbations (including severe events that
require inpatient treatment), while receiving guideline-
recommended, long-term maintenance therapy for COPD.
Reducing the impact of COPD exacerbations is of major
concern in the United States; in 2009 alone, there were
698,836 hospitalizations for COPD in non-Federal hospitals,
with the average length of stay being 4.7 days [45]. A
retrospective, cross-sectional analysis of managed-care
administrative claims data in the United States
(N Z 42,565 for patients with COPD in the commercial
claims dataset) found that 13.9% of patients experiencingat least one COPD exacerbation were managed as an
inpatient and, within that group, 4.5% of patients had an ER
visit. Exacerbation frequency and healthcare service use
has also been shown to increase with disease complexity
[46]. The huge burden of COPD exacerbations is similarly
observed in other countries: in the United Kingdom, for
example, up to 10% of all hospital admissions have been
attributed to COPD, totaling 100,000 per year, with an
average length of stay of 1 week [47]. An economic analysis
of data from a large-scale international survey found that
the majority (52e84%) of direct costs were attributable to
hospitalization in five of the seven nations studied,
including the United States. Regional differences in
healthcare practices will affect hospitalization rates for
exacerbations; for example, ER therapy may be more
aggressive in Canada than in the United States, which may
reduce subsequent admissions [24,25]; in the United
Kingdom, early discharge rates have increased through the
provision of “hospital-at-home” care services [42], a
concept initiated in France in the 1960s [48].
In general, a previous COPD exacerbation (especially a
hospitalized exacerbation) is a strong predictor of the like-
lihood of a subsequent exacerbation [7], while age, male
gender, and certain comorbid conditions are also associated
with an increased risk of death and rehospitalization in
1920 A. Anzueto et al.patients discharged after a severe COPD exacerbation [49].
In the United States, the 30-day readmission rate for COPD
has been estimated at around 7% (20% for all causes) [45],
with a 1-year readmission rate of approximately 25% and 1-
year mortality at approximately 21% [45].
Evaluating the likelihood of rehospitalization following a
COPD exacerbation (and other risk factors for subsequent
events) was beyond the scope of our pooled analysis.
Further limitations were that our analysis did not examine
how COPD exacerbations were managed during the trials,
or whether adjustments to concomitant medications influ-
enced the timing or rate of events in the tiotropium or
placebo arms. Further research is warranted into the in-
terventions employed in the outpatient and inpatient
setting for COPD exacerbations and their correspondence
with US-specific and global guideline recommendations.
This information would help inform interventions to avoid
subsequent exacerbations or to minimize their impact.
Particular strengths from this pooled analysis include the
large body of data from several trials using similar entry
criteria, a uniform definition of exacerbations, and uniform
assessment tools across a broad range of COPD severity.
Confining the data to those obtained in the United States
also reduces the heterogeneity of healthcare practice
patterns and systems that may influence the use of re-
sources by which exacerbations are often defined (e.g.,
systemic corticosteroid or antibiotic use).
Our assessments of AEs and mortality showed tiotropium
to be well tolerated, in accordance with previous analyses
[50]. Tiotropium was not associated with an increased risk
of cardiac disorders or fatal AEs.Conclusions
Tiotropium significantly reduced the risk and rate of COPD
exacerbations and hospitalized exacerbations in patients
with COPD in the United States, supporting current COPD
management guidelines, which recommend long-acting
bronchodilator therapy for the prevention and manage-
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